UC San Diego
Exploiting the promiscuity of imatinib
- Author(s): Lee, SJ
- Wang, JYJ
- et al.
Published Web Locationhttps://doi.org/10.1186/jbiol134
The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor. © 2009 BioMed Central Ltd.
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.